![Chris Valosky](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chris Valosky
Vendite & Marketing presso PEAR THERAPEUTICS, INC.
Profilo
Chris Valosky is currently the VP-Sales, Marketing & Commercial Partnership at Pear Therapeutics, Inc. Previously, he worked as the Senior Director-Marketing at Millennium Pharmaceuticals, Inc. He completed his undergraduate degree at The Ohio State University and earned an MBA from Kelley School of Business.
Posizioni attive di Chris Valosky
Società | Posizione | Inizio |
---|---|---|
PEAR THERAPEUTICS, INC. | Vendite & Marketing | - |
Precedenti posizioni note di Chris Valosky
Società | Posizione | Fine |
---|---|---|
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Vendite & Marketing | - |
Formazione di Chris Valosky
Kelley School of Business | Masters Business Admin |
The Ohio State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Pear Therapeutics, Inc.
![]() Pear Therapeutics, Inc. Medical SpecialtiesHealth Technology Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Chris Valosky